Merck reports Phase 3 survival win for sac-TMT in advanced gastroesophageal cancer

On November 20, 2026, Merck reported that its Phase 3 TroFuse-015 trial met its primary endpoint:
sacituzumab tirumotecan (sac-TMT) significantly and meaningfully improved overall survival versus treatment chosen by physicians.

The trial enrolled 473 people with locally advanced, unresectable or metastatic gastroesophageal adenocarcinoma—including gastric, gastroesophageal-junction and esophageal cancers—after at least two prior lines of systemic therapy.

The comparison treatments included trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Merck said the survival benefit was generally consistent across subgroups, regardless of TROP2 expression.

There were caveats:
sac-TMT did not meet the secondary progression-free-survival endpoint. Response rates nominally favored sac-TMT, but that result was not formally tested under the study’s analysis plan.

Merck said no new safety concerns emerged. Detailed results have not yet been released; the company plans to present them at a future medical meeting. TroFuse-015 is the second positive Phase 3 result reported in Merck’s TroFuse program.

Sources:

Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma - Merck.com

Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial

Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer

News Archive - Merck.com

Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer | BioPharm International

Berliner Volksbank eG

Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial

MSD’s ADC gains OS win but PFS miss in Phase III stomach cancer trial

Merck Phase 3 Trial Shows Survival Benefit in Advanced Cancer

Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer | Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways

Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer - Merck.com

Why Is Merck Stock Trading Higher Today? - Merck & Co (NYSE:MRK)

Berliner Volksbank eG

Brutalist Biotech